TY - JOUR
T1 - Two infants with tuberculid associated with Kawasaki disease
AU - Yamada, Hiroko
AU - Ohta, Haruka
AU - Hasegawa, Shunji
AU - Azuma, Yoshihiro
AU - Hasegawa, Masanari
AU - Kadoya, Ryo
AU - Ohbuchi, Noriko
AU - Ohnishi, Yuji
AU - Okada, Seigo
AU - Hoshide, Madoka
AU - Ohga, Shouichi
N1 - Publisher Copyright:
© 2016 The Author(s). Published with license by Taylor & Francis © Hiroko Yamada, Haruka Ohta, Shunji Hasegawa, Yoshihiro Azuma, Masanari Hasegawa, Ryo Kadoya, Noriko Ohbuchi, Yuji Ohnishi, Seigo Okada, Madoka Hoshide, and Shouichi Ohga.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Bacille de Calmette et Guerin (BCG) is the only licensed tuberculosis vaccine to prevent severe tuberculosis. The adverse events of BCG vaccination, including local reactions, lymphadenitis, osteomyelitis, tuberculid, and disseminated infection, have been reported. Two infants presented erythema at the inoculation site of BCG after the resolution of Kawasaki disease (KD). They received BCG vaccination 1 week and 6 weeks before the KD onset, respectively. Intravenous immunoglobulin improved the KD activity, however the skin rash of BCG inoculation site extended to the face and extremities days 24 and 10 after the KD onset, respectively. Both bacteriological study and interferon-γ release assay were negative for Mycobacterium tuberculosis infection. These patients were diagnosed as having tuberculid after KD. The skin lesions gradually disappeared without antibiotic therapy over 2 months. The development of tuberculid in these patients might be associated with the remnant immune activation of KD.
AB - Bacille de Calmette et Guerin (BCG) is the only licensed tuberculosis vaccine to prevent severe tuberculosis. The adverse events of BCG vaccination, including local reactions, lymphadenitis, osteomyelitis, tuberculid, and disseminated infection, have been reported. Two infants presented erythema at the inoculation site of BCG after the resolution of Kawasaki disease (KD). They received BCG vaccination 1 week and 6 weeks before the KD onset, respectively. Intravenous immunoglobulin improved the KD activity, however the skin rash of BCG inoculation site extended to the face and extremities days 24 and 10 after the KD onset, respectively. Both bacteriological study and interferon-γ release assay were negative for Mycobacterium tuberculosis infection. These patients were diagnosed as having tuberculid after KD. The skin lesions gradually disappeared without antibiotic therapy over 2 months. The development of tuberculid in these patients might be associated with the remnant immune activation of KD.
UR - http://www.scopus.com/inward/record.url?scp=84991515491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991515491&partnerID=8YFLogxK
U2 - 10.1080/21645515.2016.1208329
DO - 10.1080/21645515.2016.1208329
M3 - Article
C2 - 27435523
AN - SCOPUS:84991515491
VL - 12
SP - 2772
EP - 2776
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
SN - 2164-5515
IS - 11
ER -
